NYSE$MED

Medifast Inc · Q4 2023 earnings

Q4 2023 earnings · · Investor relations

Briefing

Medifast reported a decrease in revenue and earnings per share for Q4 2023, driven by a decline in active earning OPTAVIA Coaches and their productivity, while also making strategic investments in marketing and medically-supported weight loss initiatives.

Medifast's Q4 2023 revenue decreased by 43.4% to $191.0 million compared to Q4 2022. Net income also decreased to $6.0 million, or $0.55 per diluted share. The decline was primarily due to a decrease in the number of active earning OPTAVIA Coaches and a decline in productivity per coach. The company is focusing on business realignment and investments in customer acquisition and medically-supported weight loss.

  • Q4 revenue decreased by 43.4% year-over-year to $191.0 million.
  • Net income for Q4 was $6.0 million, or $0.55 per diluted share.
  • The number of active earning OPTAVIA Coaches decreased by 32.5% to 41,100.
  • Average revenue per active earning OPTAVIA Coach decreased by 16.1% to $4,648.

Headline financials

Total Revenue

$191M

Previous: $337M-43.4%
EPS (adj)

$1.09

Previous: $3.70-70.5%
Independent active earning coaches

41.1K

Previous: 60.9K-32.5%
Average revenue per active earning coach

$4.65K

Previous: $5.54K-16.1%
Capital Expenditures

-$946K

Previous: $9.06M-110.4%
Net Income

$6M

Previous: $26.5M-77.4%
Operating Income

$8.68M

Previous: $32.6M-73.4%
Gross Profit

$141M

Previous: $234M-39.5%
Stock-Based Comp

$2.39M

Previous: $2.95M-18.9%

Revenue & EPS history

Medifast · Revenue · Quarterly

$191M

Q4 2023-43.4%vs Q4 2022
Beat estimate in 14 of 15 quarters(93%)
ActualEstimate

Forward guidance

The company expects first quarter 2024 revenue to be in the range of $155 million to $175 million and first quarter 2024 diluted EPS to be in the range of $0.25 to $0.95. The EPS range excludes the costs related to the initiation of the LifeMD collaboration and any gains or losses from changes in the market price of the company’s LifeMD common stock investment.

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 20 quarterly earnings reports · overlaid with Q4 2023

Historical avgQ4 2023

+0.2%

Avg return

Earnings day

+0.5%

Avg return

5 days after

+0.4%

Avg return

30 days after

51%

33 / 65 earnings

Positive

+31.6%

Q4 2017

Best reaction

-29.9%

Q3 2019

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q1 2026+0.2%+19.7%+16.7%
Q4 2025-0.8%-1.9%-7.4%
Q3 2025+0.8%+0.4%-8.6%
Q1 2025-0.6%+5.3%+10.8%
Q4 2024-11.4%-8.4%-11.1%
Q3 2024+9.8%+3.1%+6.2%
Q2 2024-5.6%-9.0%-11.8%
Q1 2024-18.3%-20.8%-25.4%
Q4 2023-19.2%-18.5%-28.7%
Q3 2023-1.5%-6.5%+3.3%
Q2 2023-9.5%-4.9%-18.5%
Q1 2023-3.8%-0.7%-14.1%
Q4 2022-10.8%-4.6%-15.3%
Q3 2022-3.2%-1.6%+9.0%
Q2 2022-15.2%-21.9%-31.9%
Q1 2022+5.4%+1.8%-2.0%
Q4 2021-5.6%+1.7%-6.4%
Q3 2021+3.7%+4.7%-7.1%
Q2 2021-8.7%-14.1%-17.4%
Q1 2021+7.8%+18.9%+35.3%
Q4 2020-3.9%-0.8%-14.7%
Q3 2020+12.9%+23.5%+45.4%
Q2 2020-5.7%-5.0%-8.0%
Q1 2020+18.5%+30.1%+46.7%
Q4 2019-9.7%-13.4%-31.5%
Q3 2019-29.9%-24.8%-14.7%
Q2 2019-7.6%-7.8%-10.5%
Q1 2019-2.1%+3.6%-12.1%
Q4 2018+0.9%-0.7%+0.3%
Q3 2018-28.3%-25.3%-32.4%
Q2 2018+25.8%+17.4%+35.0%
Q1 2018+22.3%+19.3%+50.0%
Q4 2017+31.6%+32.5%+44.0%
Q3 2017+14.7%+13.1%+16.6%
Q2 2017+18.6%+20.7%+31.7%
Q1 2017+3.4%+3.8%-6.1%
Q4 2016-3.7%-4.4%-1.4%
Q3 2016-5.0%-4.5%-4.7%
Q2 2016-0.2%+0.8%+5.9%
Q1 2016+0.8%
Q4 2015-5.6%
Q3 2015+6.9%
Q2 2015-9.2%
Q1 2015+5.3%
Q4 2014-3.1%
Q3 2014+2.5%
Q2 2014-9.5%
Q1 2014-8.5%
Q4 2013+3.4%
Q3 2013+0.5%
Q2 2013-4.3%
Q1 2013-3.8%
Q4 2012-5.4%
Q3 2012+10.4%
Q2 2012+28.5%
Q1 2011+8.9%
Q1 2012+3.2%
Q4 2011+0.9%
Q4 2009+0.9%
Q3 2010+1.9%
Q3 2011+1.9%
Q4 2010+4.3%
Q2 2010+4.3%
Q2 2011+4.3%
Q1 2010+10.1%

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro